All Veterinary medicines articles
-
JournalNew data protection for maximum residue limits
Regulatory Rapporteur March 2024 | Volume 21 | No.3 Abstract Maximum residue limits (MRL) have been a requirement for all substances included in veterinary medicines intended for food-producing animals since the 1990s. The new Veterinary Medicines Regulation ([EU] 2019/6) ...
-
Industry newsAUS-UK joint agency vetmed approval process agreed
The UK’s VMD and Australia’s APVMA have published guidance for the simultaneous review of veterinary medicines submissions.
-
JournalVM5: Digital innovation to support animal health
Regulatory Rapporteur December 2023 | Volume 20 | No.11 Session leader: Jana Schalansky, Head of Veterinary Strategic Support, Veterinary Medicines Division, EMA, the Netherlands. Speakers: Ricardo Carapeto García, Head of Area and Environmental Risks, AEMPS, ...
-
JournalVM4: Living with post-authorisation obligations – progress, challenges and future opportunities
Regulatory Rapporteur December 2023 | Volume 20 | No.11 Session leaders: João Pedro Duarte da Silva, Senior Officer, Veterinary Medicines Unit, General Directorate for Food and Veterinary (DGAV), Portugal. Speakers: Katherine Schirmann, Scientific Officer, The ...
-
JournalVM3: Regulatory exchange and new/future approaches
Regulatory Rapporteur December 2023 | Volume 20 | No.11 Session leaders: Dr Mel Munro, Global Lead, Regulatory Science, knoell Animal Health, UK. Speakers: Beate Gasser, CMDv Vice Chair, Austrian Federal Office for Safety in ...
-
JournalVM2: New initiatives in regulatory science
Regulatory Rapporteur December 2023 | Volume 20 | No.11 Speakers: Raffaele Bruno, Associate Director, Regulatory Affairs, Zoetis Inc., Belgium. Michael Empl, Scientific Specialist, Toxicology & Environmental Risk Assessment, European Medicines Agency, Netherlands. Tony Humphreys, Head of ...
-
JournalVM1:
Horizontal legislation and
veterinary medicine availabilityRegulatory Rapporteur December 2023 | Volume 20 | No.11 Session leaders: Rick Clayton, Technical Director, AnimalhealthEurope, Belgium. Speakers: Jaume Colomer, Senior Technical Manager, AnimalhealthEurope, Belgium. Nancy De Briyne, Executive Director of the Federation of Veterinarians ...
-
JournalTransition to the new QRD template for veterinary medicines: challenges and opportunities
The product information template version 9 (QRD v.9) supports the requirements of the Veterinary Medicinal Products Regulation (EU) 2019/6[1] (VMR), which has applied since 28 January 2022. Considering the high workload and costs associated with the quality review document (QRD) updates, the huge number of veterinary medicinal products (VMPs) concerned, ...
-
EditorialVeterinary medicines: the challenges of new regulation
Regulatory Rapporteur October 2023 | Volume 20 | No.9 The October 2023 edition of TOPRA’s journal – Regulatory Rapporteur – focuses on topics and developments specific for veterinary medicines: From the challenging aspects arising ...
-
-
Industry newsEMA future ‘VetMeds’ for healthy animals and humans; seminar
In the lead up to the EMA’s Veterinary Awareness Day, Ivo Classen sits down to discuss the agency’s progress in the field of veterinary medicines.
-
Industry newsHuman COVID drug set to treat FCov-23 coronavirus in cats
A virulent strain of feline coronavirus has spread through Cyprus, and veterinarians on the island have received a first batch of anti-COVID pills.
-
JournalReappraisal of regulation of agricultural and veterinary chemicals in Australia
Agricultural and Veterinary (Agvet) chemical products are registered with the Australian Pesticides and Veterinary Medicines Authority (APVMA) before they can be supplied in Australia. A mandatory scheme was introduced by the Australian government in 1993 to transfer Agvet chemical products from the State-based system to a national ...
-
JournalVM1: Availability and Innovation - under a new VMP legislation
The requirements for quality data for LM products have increased under the new Regulation. It is difficult to determine which regulatory framework is most appropriate for novel ATMs.
-
JournalVM2: Novel therapies in animal health – Balancing guidance versus gaining flexibility
The new EU Veterinary Medicines Regulation contains specific provision for novel therapies. Established methodologies for demonstrating quality, safety and efficacy of veterinary medicinal products often cannot be applied to novel therapies.
-
JournalVM3: Antimicrobials; the new rules, their impact and consequences
The Veterinary Regulation 2019/6 established new provisions and obligations for antimicrobials in veterinary medicines. Work on implementing regulations and guidelines is ongoing to further specify their use and restrictions.
-
JournalVM4: Regulatory update and perspectives: Variations, packaging and labelling, pharmacovigilance
Industry is navigating through complex new rules and opportunities for variations and will require continued cooperation. The year 2023 is expected to show the benefits of the revised pharmacovigilance procedures in practice.
-
Meeting ReportVM5: CVMP Guidelines Update:
Data protection (Article 40.5),
prescription status (Article.34) and benefit-riskThe secondary legislation and guidelines are as critical as Regulation 2019/6 itself in defining the future landscape for animal health in the EU. The concept and definitions of benefit-risk affect many different aspects of veterinary medicines regulation, as per the legislation.
-
InterviewA strong advocate for global harmonisation in animal health
Gavin Hall, Interim Director of Authorisations at the Veterinary Medicines Directorate, discusses the agency’s drive to harmonise scientific guidelines and its readiness to be flexible with regulatory frameworks following Brexit.
-
Meeting ReportThe EMA’s Veterinary Big Data Stakeholder Forum (Part 2)
The Veterinary Big Data Stakeholder Forum, the first event of its kind and jointly organised by the European Medicines Agency and Heads of Medicines Agencies, took place on 1–2 June 2021 as a virtual event with more than 500 participants globally connected. This is the second and final part of the meeting report; the first half was published in Volume 19 No. 1 of Regulatory Rapporteur.